Madrigal Pharmaceuticals, Inc.
MDGL
Classement en actions
#2003
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Prix de l'action
$451.08
Dernière synchronisation: 2026-10-16
Capitalisation boursière
$10.42B
Changement (1 jour)
-1.90%
Changement (1 an)
2.77%
Pays
US
Échange Madrigal Pharmaceuticals, Inc. (MDGL)
Catégorie
Healthcare
EPS pour Madrigal Pharmaceuticals, Inc. (MDGL)
EPS au June 2026 TTM : $-12.89
Selon les derniers rapports financiers et le cours de l'action de Madrigal Pharmaceuticals, Inc., l’EPS actuel de la société (TTM) est de $-12.89. À la fin de 2023, la société avait un EPS de $-19.99 une augmentation par rapport à celui de 2022, qui était de $-17.23.
Historique de l'EPS de Madrigal Pharmaceuticals, Inc. de 2001 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $-12.89 | -41.14% |
| 2024 | $-21.90 | 9.55% |
| 2023 | $-19.99 | 16.02% |
| 2022 | $-17.23 | 17.77% |
| 2021 | $-14.63 | 11.76% |
| 2020 | $-13.09 | 176.74% |
| 2019 | $-4.73 | 113.06% |
| 2018 | $-2.22 | -12.60% |
| 2017 | $-2.54 | -49.90% |
| 2016 | $-5.07 | -98.74% |
| 2015 | $-401.56 | 1,211.43% |
| 2014 | $-30.62 | -31.16% |
| 2013 | $-44.48 | 20.25% |
| 2012 | $-36.99 | 5.26% |
| 2011 | $-35.14 | 8.16% |
| 2010 | $-32.49 | -139.84% |
| 2009 | $81.55 | -184.87% |
| 2008 | $-96.09 | 40.38% |
| 2007 | $-68.45 | -23.97% |
| 2006 | $-90.03 | -16.88% |
| 2005 | $-108.31 | 26.00% |
| 2004 | $-85.96 | 92.52% |
| 2003 | $-44.65 | -57.51% |
| 2002 | $-105.09 | 2,209.67% |
| 2001 | $-4.55 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | -234.37% |
US
|
|
| $-7.98 | -38.09% |
US
|
|
| $-5.29 | -58.96% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -315.21% |
NL
|
